These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38597214)

  • 1. Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trial.
    Aubin HJ; Berlin I; Guiraud J; Bruhwyler J; Batel P; Perney P; Trojak B; Bendimerad P; Guillou M; Bisch M; Grall-Bronnec M; Labarrière D; Delsart D; Questel F; Moirand R; Bernard P; Trovero F; Pham HP; Tassin JP; Puech A
    Addiction; 2024 Jul; 119(7):1211-1223. PubMed ID: 38597214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized, Placebo-controlled, Clinical Trial of Prazosin for the Treatment of Alcohol Use Disorder.
    Wilcox CE; Tonigan JS; Bogenschutz MP; Clifford J; Bigelow R; Simpson T
    J Addict Med; 2018; 12(5):339-345. PubMed ID: 29664896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moderation of Prazosin's Efficacy by Alcohol Withdrawal Symptoms.
    Sinha R; Wemm S; Fogelman N; Milivojevic V; Morgan PM; Angarita GA; Hermes G; Fox HC
    Am J Psychiatry; 2021 May; 178(5):447-458. PubMed ID: 33207935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder.
    Simpson TL; Saxon AJ; Stappenbeck C; Malte CA; Lyons R; Tell D; Millard SP; Raskind M
    Am J Psychiatry; 2018 Dec; 175(12):1216-1224. PubMed ID: 30153753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder.
    Verplaetse TL; Ralevski E; Roberts W; Gueorguieva R; McKee SA; Petrakis IL
    Alcohol Clin Exp Res; 2019 Apr; 43(4):741-746. PubMed ID: 30698839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Combination of Marketed Antagonists of α1b-Adrenergic and 5-HT2A Receptors Inhibits Behavioral Sensitization and Preference to Alcohol in Mice: A Promising Approach for the Treatment of Alcohol Dependence.
    Trovero F; David S; Bernard P; Puech A; Bizot JC; Tassin JP
    PLoS One; 2016; 11(3):e0151242. PubMed ID: 26968030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled clinical trial of prazosin for alcohol use disorder in active duty soldiers: Predictive effects of elevated cardiovascular parameters.
    Raskind MA; Williams T; Holmes H; Hart K; Crews L; Poupore EL; Thomas RG; Darnell J; Daniels C; Goke K; Hendrickson R; Terry G; Mayer C; Simpson T; Saxon A; Rasmussen D; Peskind ER
    Alcohol Clin Exp Res (Hoboken); 2023 Feb; 47(2):348-360. PubMed ID: 36809662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder.
    Simpson TL; Malte CA; Dietel B; Tell D; Pocock I; Lyons R; Varon D; Raskind M; Saxon AJ
    Alcohol Clin Exp Res; 2015 May; 39(5):808-17. PubMed ID: 25827659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial.
    Collins SE; Duncan MH; Saxon AJ; Taylor EM; Mayberry N; Merrill JO; Hoffmann GE; Clifasefi SL; Ries RK
    Lancet Psychiatry; 2021 Apr; 8(4):287-300. PubMed ID: 33713622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence.
    Simpson TL; Saxon AJ; Meredith CW; Malte CA; McBride B; Ferguson LC; Gross CA; Hart KL; Raskind M
    Alcohol Clin Exp Res; 2009 Feb; 33(2):255-63. PubMed ID: 18945226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety.
    Falk DE; Ryan ML; Fertig JB; Devine EG; Cruz R; Brown ES; Burns H; Salloum IM; Newport DJ; Mendelson J; Galloway G; Kampman K; Brooks C; Green AI; Brunette MF; Rosenthal RN; Dunn KE; Strain EC; Ray L; Shoptaw S; Ait-Daoud Tiouririne N; Gunderson EW; Ransom J; Scott C; Leggio L; Caras S; Mason BJ; Litten RZ;
    Alcohol Clin Exp Res; 2019 Jan; 43(1):158-169. PubMed ID: 30403402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prazosin for Veterans with Posttraumatic Stress Disorder and Comorbid Alcohol Dependence: A Clinical Trial.
    Petrakis IL; Desai N; Gueorguieva R; Arias A; O'Brien E; Jane JS; Sevarino K; Southwick S; Ralevski E
    Alcohol Clin Exp Res; 2016 Jan; 40(1):178-86. PubMed ID: 26683790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
    Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
    CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings.
    Fox HC; Anderson GM; Tuit K; Hansen J; Kimmerling A; Siedlarz KM; Morgan PT; Sinha R
    Alcohol Clin Exp Res; 2012 Feb; 36(2):351-60. PubMed ID: 21919922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial.
    Anton RF; Latham P; Voronin K; Book S; Hoffman M; Prisciandaro J; Bristol E
    JAMA Intern Med; 2020 May; 180(5):728-736. PubMed ID: 32150232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial.
    Kenna GA; Haass-Koffler CL; Zywiak WH; Edwards SM; Brickley MB; Swift RM; Leggio L
    Addict Biol; 2016 Jul; 21(4):904-14. PubMed ID: 26037245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining the α1 -adrenergic receptor antagonist, prazosin, with the β-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone.
    Rasmussen DD; Beckwith LE; Kincaid CL; Froehlich JC
    Alcohol Clin Exp Res; 2014 Jun; 38(6):1532-9. PubMed ID: 24891220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial.
    Akhondzadeh S; Erfani S; Mohammadi MR; Tehrani-Doost M; Amini H; Gudarzi SS; Yasamy MT
    J Clin Pharm Ther; 2004 Apr; 29(2):145-50. PubMed ID: 15068403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.